Education
About Us
Working with TipRanks
Follow Us
Acotec Scientific Holdings Limited (HK:6669)
:6669
6669 Stock Chart & Stats
HK$14.16
-HK$0.14(-2.42%)
At close: 4:00 PM EST
HK$14.16
-HK$0.14(-2.42%)
Day’s Range― - ―
52-Week RangeHK$6.29 - HK$15.47
Previous CloseN/A
Volume343.13K
Average Volume (3M)462.19K
Market Cap
HK$4.32B
Enterprise ValueHK$3.27B
Total Cash (Recent Filing)HK$995.38M
Total Debt (Recent Filing)HK$236.13M
Price to Earnings (P/E)38.2
Beta0.92
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding313,389,160
10 Day Avg. Volume400,669
30 Day Avg. Volume462,190
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.25
Price to Sales (P/S)3.16
P/FCF Ratio317.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$15.00Price Target Upside5.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.8
Revenue Forecast (FY)HK$5.54B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 75.23% gross margin signals strong product-level profitability and likely differentiated, high-value consumables in vascular intervention. Durable margin strength supports reinvestment in R&D and manufacturing scale, providing pricing flexibility and competitive cushioning over time.
Robust Free Cash Flow GrowthSignificant FCF expansion and near-parity of operating cash flow with net income indicate strong cash conversion. Durable cash generation reduces reliance on external financing, funds capex and product development, and gives flexibility for strategic investments or opportunistic M&A over the medium term.
Conservative Balance SheetVery low leverage and a high equity ratio provide a solid capital structure to absorb demand swings and support growth investments. This conservatism preserves financial flexibility, reduces refinancing risk, and allows management to pursue long-term product commercialization without pressuring cash flows.
Bears Say
Modest Net Profit MarginA 17.02% net margin, while positive, lags the firm’s very high gross margin and implies significant operating costs or lower operating leverage. Unless SG&A and other expenses are controlled, net margin compression could limit retained earnings and long-term return generation for shareholders.
Moderate Return On EquityROE of 7.22% is modest given strong gross margins and improving cash flow, indicating the company may not be fully converting assets or equity into high returns. Over months, absent efficiency gains or better margin conversion, shareholder return prospects could remain subdued versus peers.
No Dividend YieldLack of a dividend reduces appeal to income investors and narrows the shareholder base to growth-seeking holders. Structurally, without a clear payout policy, the company must continually justify capital allocation via reinvestment or buybacks to maintain investor support over the medium term.
Acotec Scientific Holdings Limited News
6669 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
Acotec Scientific Holdings Limited lowest stock price was HK$6.29 and its highest was HK$15.47 in the past 12 months.
What is Acotec Scientific Holdings Limited’s market cap?
Acotec Scientific Holdings Limited’s market cap is HK$4.32B.
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
Acotec Scientific Holdings Limited’s upcoming earnings report date is Mar 30, 2026 which is in 35 days.
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Acotec Scientific Holdings Limited released its earnings results on Aug 26, 2025. The company reported HK$0.317 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.317.
Is Acotec Scientific Holdings Limited overvalued?
According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Undervalued.
Does Acotec Scientific Holdings Limited pay dividends?
Acotec Scientific Holdings Limited does not currently pay dividends.
What is Acotec Scientific Holdings Limited’s EPS estimate?
Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acotec Scientific Holdings Limited have?
Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Acotec Scientific Holdings Limited reported an EPS of HK$0.317 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.219%.
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
Currently, no hedge funds are holding shares in HK:6669
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.
6669 Stock 12 Month Forecast
Average Price Target
HK$15.00
▲(5.93% Upside)
Technical Analysis
Peijia Medical Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---